Accéder au contenu
Merck

Exposure to Static Magnetic and Electric Fields Treats Type 2 Diabetes.

Cell metabolism (2020-10-08)
Calvin S Carter, Sunny C Huang, Charles C Searby, Benjamin Cassaidy, Michael J Miller, Wojciech J Grzesik, Ted B Piorczynski, Thomas K Pak, Susan A Walsh, Michael Acevedo, Qihong Zhang, Kranti A Mapuskar, Ginger L Milne, Antentor O Hinton, Deng-Fu Guo, Robert Weiss, Kyle Bradberry, Eric B Taylor, Adam J Rauckhorst, David W Dick, Vamsidhar Akurathi, Kelly C Falls-Hubert, Brett A Wagner, Walter A Carter, Kai Wang, Andrew W Norris, Kamal Rahmouni, Garry R Buettner, Jason M Hansen, Douglas R Spitz, E Dale Abel, Val C Sheffield, Calvin S Carter, Sunny C Huang, Charles C Searby, Benjamin Cassaidy, Michael J Miller, Wojciech J Grzesik, Ted B Piorczynski, Thomas K Pak, Susan A Walsh, Michael Acevedo, Qihong Zhang, Kranti A Mapuskar, Ginger L Milne, Antentor O Hinton, Deng-Fu Guo, Robert Weiss, Kyle Bradberry, Eric B Taylor, Adam J Rauckhorst, David W Dick, Vamsidhar Akurathi, Kelly C Falls-Hubert, Brett A Wagner, Walter A Carter, Kai Wang, Andrew W Norris, Kamal Rahmouni, Garry R Buettner, Jason M Hansen, Douglas R Spitz, E Dale Abel, Val C Sheffield
RÉSUMÉ

Aberrant redox signaling underlies the pathophysiology of many chronic metabolic diseases, including type 2 diabetes (T2D). Methodologies aimed at rebalancing systemic redox homeostasis have had limited success. A noninvasive, sustained approach would enable the long-term control of redox signaling for the treatment of T2D. We report that static magnetic and electric fields (sBE) noninvasively modulate the systemic GSH-to-GSSG redox couple to promote a healthier systemic redox environment that is reducing. Strikingly, when applied to mouse models of T2D, sBE rapidly ameliorates insulin resistance and glucose intolerance in as few as 3 days with no observed adverse effects. Scavenging paramagnetic byproducts of oxygen metabolism with SOD2 in hepatic mitochondria fully abolishes these insulin sensitizing effects, demonstrating that mitochondrial superoxide mediates induction of these therapeutic changes. Our findings introduce a remarkable redox-modulating phenomenon that exploits endogenous electromagneto-receptive mechanisms for the noninvasive treatment of T2D, and potentially other redox-related diseases.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Albumine de sérum bovin, lyophilized powder, ≥96% (agarose gel electrophoresis)
Sigma-Aldrich
Dexaméthasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Acide borique, BioReagent, for molecular biology, suitable for cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
Acide perchlorique, 70%, 99.999% trace metals basis
Sigma-Aldrich
D-Glucose 6-phosphate sodium salt, ≥98% (HPLC)
Sigma-Aldrich
Glutaraldéhyde solution, Grade I, 70% in H2O, specially purified for use as an electron microscopy fixative or other sophisticated use
Sigma-Aldrich
Thioredoxin Reductase Assay Kit, 1 kit sufficient for 100 assays (1 mL)
Sigma-Aldrich
3-Deoxy-2-keto-6-phosphogluconic acid lithium salt, ≥95% (TLC)